1 to 10 of 21
Sort by

Library Entry
Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma

Neuroblastoma (NB) is the most frequent extracranial solid tumor in children. More than 50% of patients present with widespread (stage M) or refractory disease. In these patients, event-free and overall survival was improved by the addition of the anti-disialoganglioside antibody dinutuximab...

Library Entry
Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trial

Natural killer (NK) cells are one of the main effector populations of immunotherapy with monoclonal antibody and cytokines, used in combination with chemotherapy to treat children with high-risk neuroblastoma on this phase II trial. However, the impact of chemoimmunotherapy on NK cell kinetics,...

Library Entry
SITC 31st Annual Meeting (2016): Concurrent Session II: Tumor Immunology 101 (Nurse/Pharmacist Track)

The Society for Immunotherapy of Cancer (SITC) hosted "Concurrent Session II: Tumor Immunology 101 (Nurse/Pharmacist Track)" during the SITC 31st Annual Meeting & Associated Programs on November 11-13, 2016. Available here are the presentation slides and video from the session. Co...

6 attachments

Library Entry
SITC 27th Annual Meeting Primer

The Society for Immunotherapy of Cancer (SITC) 27 th Annual Meeting: Primer on Tumor Immunology and Cancer Immunotherapy TM October 25, 2012 Bethesda North Marriott Hotel & Convention Center North Bethesda, MD Program Organizers Charles Drake, MD, PhD - Johns Hopkins University ...

7 attachments